LONDON, Nov. 20, 2017 -- The global molecular cytogenetics market will grow at a CAGR of 11% from 2017 to 2022 to reach USD 2,266.4 million by 2022, according to the publication from Meticulous Research™. The molecular cytogenetics market is driven by increasing focus on preventive healthcare measures, growing genetic abnormalities, increasing aging population and subsequent rise in various chronic diseases, growing need to reduce mounting healthcare cost, and increasing focus on clinical and research diagnosis. Moreover, increasing focus on targeted based therapies and growing predictive and presymptomatic genetic testing further provides significant opportunities in this market. However, lack of awareness about diagnostic technologies, high cost of diagnosis, unfavourable reimbursement scenario, and technical limitations and complexities of the equipment have embraced the growth of molecular cytogenetics market globally.
The global molecular cytogenetics market is mainly segmented by technique (fluorescence in situ hybridization, comparative genomic hybridization, in situ hybridization, karyotyping, and banding techniques), by product (instruments, kits and reagents, software, services, and consumable/accessories ), by application (oncology, genetic disorders, personalized medicines, and other), and by end user (pharmaceuticals and biotechnological companies, clinical and diagnostic laboratories, and academic institutes).
Request Sample Report: http://www.meticulousresearch.com/request-sample-report/?cp_id=3067
Geographically, the global molecular cytogenetics market is segmented into five major regions, namely North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America accounted for the major share in the global molecular cytogenetics market in 2016, followed by Europe, and Asia-Pacific region. The large share of this region is primarily attributed to the increased funding for medical research, stringent drug development regulations which demand molecular cytogenetics techniques, growing aging population and thereby prevalence of various chronic diseases, and direct & indirect financial investments in the pharma biotech companies.
The key players in the global molecular cytogenetics market are Thermo Fisher Scientific, Abbott Laboratories, Agilent Technologies, PerkinElmer, Bio-Rad Laboratories, Applied Spectral Imaging, Quest Diagnostics, Roche Diagnostics, Danaher Corporation, Illumina, and Oxford Gene Technology.
Full News: http://www.meticulousresearch.com/molecular-cytogenetics-market-2022/
Scope of the report
Market by Techniques
- Fluorescence In Situ Hybridization
- Comparative Genomic Hybridization (CGH)
-- Chromosomal CGH
-- Array-Based CGH - In Situ Hybridization
- Karyotyping
-- Spectral Karyotyping
-- Virtual Karyotyping - Banding Techniques
-- G banding
-- Q banding
-- R banding
-- C banding
-- T banding
Market by Product
- Instruments
-- Systems
-- Imagers and Scanners - Kits and Reagents
-- Testing Kits
-- Probes
-- Reagents - Software
- Services
- Consumables/Accessories
Market by Application
- Oncology
- Genetic Disorders
- Personalized Medicines
- Others
Market by End User:
- Pharmaceutical and Biotechnological companies
- Clinical and Diagnostic laboratories
- Academic Institutes
- Others
Browse in-depth Report on http://www.meticulousresearch.com/product/molecular-cytogenetics-market/
Contact Info:
Viren Shrivastava
AVP- Global Sales and Marketing
Meticulous Research™
Email: [email protected]
Direct Lines: +1-646-781-8004 (North America)
+44-203-868-8738 (Europe)
+91 744-7780008 (Asia-Pacific)


Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Anta Sports Expands Global Footprint With Strategic Puma Stake
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 



